These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37115038)

  • 21. Progress towards molecular-based management of childhood Langerhans cell histiocytosis.
    Héritier S; Emile JF; Hélias-Rodzewicz Z; Donadieu J
    Arch Pediatr; 2019 Jul; 26(5):301-307. PubMed ID: 31281037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.
    Gatalica Z; Bilalovic N; Palazzo JP; Bender RP; Swensen J; Millis SZ; Vranic S; Von Hoff D; Arceci RJ
    Oncotarget; 2015 Aug; 6(23):19819-25. PubMed ID: 26110571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults.
    Milne P; Bigley V; Bacon CM; Néel A; McGovern N; Bomken S; Haniffa M; Diamond EL; Durham BH; Visser J; Hunt D; Gunawardena H; Macheta M; McClain KL; Allen C; Abdel-Wahab O; Collin M
    Blood; 2017 Jul; 130(2):167-175. PubMed ID: 28512190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. OCT2 expression in histiocytoses.
    Ungureanu IA; Cohen-Aubart F; Héritier S; Fraitag S; Charlotte F; Lequain H; Hélias-Rodzewicz Z; Haroche J; Donadieu J; Emile JF
    Virchows Arch; 2023 Jul; 483(1):81-86. PubMed ID: 36754897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.
    Hyman DM; Diamond EL; Vibat CR; Hassaine L; Poole JC; Patel M; Holley VR; Cabrilo G; Lu TT; Arcila ME; Chung YR; Rampal R; Lacouture ME; Rosen N; Meric-Bernstam F; Baselga J; Kurzrock R; Erlander MG; Janku F; Abdel-Wahab O
    Cancer Discov; 2015 Jan; 5(1):64-71. PubMed ID: 25324352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between clinicopathologic characteristics and BRAF
    Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ
    Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases.
    Alayed K; Medeiros LJ; Patel KP; Zuo Z; Li S; Verma S; Galbincea J; Cason RC; Luthra R; Yin CC
    Hum Pathol; 2016 Jun; 52():61-7. PubMed ID: 26980021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequent KIT mutations in skin lesions of patients with BRAF wild-type Langerhans cell histiocytosis.
    Tóth B; Kiss N; Hársing J; Kárpáti S; Csomor J; Bödör C; Tímár J; Rásó E
    Virchows Arch; 2020 Nov; 477(5):749-753. PubMed ID: 32372223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
    Tran G; Huynh TN; Paller AS
    J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
    Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
    J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Somatic ARAF mutations in pediatric Langerhans cell histiocytosis: clinicopathologic, genetic and functional profiling.
    Liu R; Guo Y; Han L; Feng S; Cao J; Sun Y; Cao Z; Cui X
    Clin Exp Med; 2023 Dec; 23(8):5269-5279. PubMed ID: 37572153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis.
    Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y
    J Neurosurg Pediatr; 2019 Jan; 23(1):48-53. PubMed ID: 30265230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
    Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
    Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations.
    Pina-Oviedo S; Medeiros LJ; Li S; Khoury JD; Patel KP; Alayed K; Cason RC; Bowman CJ; Yin CC
    Mod Pathol; 2017 May; 30(5):734-744. PubMed ID: 28084334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy.
    Friedman JS; Durham BH; Reiner AS; Yabe M; Petrova-Drus K; Dogan A; Pulitzer M; Busam KJ; Francis JH; Rampal RK; Ulaner GA; Reddy R; Yeh R; Hatzoglou V; Lacouture ME; Rotemberg V; Mazor RD; Hershkovitz-Rokah O; Shpilberg O; Goyal G; Go RS; Abeykoon JP; Rech K; Morlote D; Fidai S; Gannamani V; Zia M; Abdel-Wahab O; Panageas KS; Rosenblum MK; Diamond EL
    Br J Haematol; 2024 Jul; 205(1):127-137. PubMed ID: 38613141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rare diseases of bone: Erdheim-Chester and Rosai-Dorfman non-Langerhans cell histiocytoses.
    Mavrogenis AF; Igoumenou VG; Antoniadou T; Megaloikonomos PD; Agrogiannis G; Foukas P; Papageorgiou SG
    EFORT Open Rev; 2018 Jun; 3(6):381-390. PubMed ID: 30034819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis.
    Janku F; Diamond EL; Goodman AM; Raghavan VK; Barnes TG; Kato S; Abdel-Wahab O; Durham BH; Meric-Bernstam F; Kurzrock R
    Mol Cancer Ther; 2019 Jun; 18(6):1149-1157. PubMed ID: 31015311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAFV600E and MAP2K1 mutations in Langerhans cell histiocytosis occur predominantly in children.
    Zeng K; Ohshima K; Liu Y; Zhang W; Wang L; Fan L; Li M; Li X; Wang Z; Guo S; Yan Q; Guo Y
    Hematol Oncol; 2017 Dec; 35(4):845-851. PubMed ID: 27597420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [An overview of histiocytosis].
    Tojo A
    Rinsho Ketsueki; 2022; 63(5):363-367. PubMed ID: 35662158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
    Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM
    JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.